In our study, 2.92% of patients receiving treatment with ALK TKIs developed all‐grade pneumonitis, 1.42% developed high‐grade pneumonitis and 0.09% developed Grade 5 pneumonitis. The gene discussed is ALK; the disease is pneumonitis.